Hepatitis B Core Antibody Positive: Interpretation and Management

Introduction to Hepatitis B Core Antibody

A positive hepatitis B core antibody (anti-HBc) indicates past or present HBV infection, but does not distinguish between acute, chronic, or resolved infection, and additional serologic markers are essential to determine the patient's current HBV status and guide management 1

The following tests are required for interpretation: HBsAg, Anti-HBs, IgM anti-HBc, and HBV DNA (if HBsAg positive or if immunosuppression planned) 1
HBsAg (hepatitis B surface antigen) is a critical marker for diagnosis 1
Anti-HBs (hepatitis B surface antibody) is essential for determining immunity 2
IgM anti-HBc (IgM antibody to core antigen) is detectable for approximately 6 months during acute infection 3

Pattern 1: Acute HBV Infection - HBsAg positive + Total anti-HBc positive + IgM anti-HBc positive 1
Pattern 2: Chronic HBV Infection - HBsAg positive + Total anti-HBc positive + IgM anti-HBc negative (or low-level positive) 1
Pattern 3: Resolved HBV Infection with Immunity - HBsAg negative + Total anti-HBc positive + Anti-HBs positive 1, 2
Pattern 4: Isolated Anti-HBc - requires careful evaluation as it may represent resolved infection with waning anti-HBs, false-positive anti-HBc, window period of acute infection, or occult HBV infection 1, 2, 4

Screen and vaccinate contacts: test all household and sexual contacts for HBsAg and anti-HBs, and vaccinate seronegative contacts immediately 1, 4
Test for coinfections: HAV serology, HCV, and HIV testing in at-risk individuals 1, 3
Assess disease activity and need for treatment: measure HBV DNA level, ALT/AST, HBeAg/anti-HBe, and refer to hepatology for management decisions 1, 3
Counsel on transmission prevention: heavy alcohol use accelerates progression to cirrhosis and HCC, cover open wounds, and clean blood spills with bleach 1, 4

Resolved infection (HBsAg negative, anti-HBc positive): assess reactivation risk before immunosuppression, and consider antiviral prophylaxis if HBV DNA detectable 1, 2
Reactivation risk: 3-45% depending on regimen, with highest risk from anti-CD20/CD52 monoclonal antibodies, high-dose corticosteroids, and hematopoietic stem cell transplant 1, 2